US Oncology Research, The US Oncology Network and McKesson Specialty Health
Affiliated Investigators Participate in Studies Featured at ASCO 2012

Studies include a variety of disease and disease states such as renal cell carcinomas, advanced HER2-positive solid tumors, melanomas, lymphomas, myelofibrosis, urothelial carcinomas, and other cancers of the prostate, colon, breast, bladder and pancreas

The Woodlands, Texas (May 29, 2012) — More than 90 leading investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in over 60 studies that will be presented, displayed or published at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 1 - 5 at McCormick Place in Chicago. Of those studies, 12 will be presented as oral presentations including a plenary session regarding prostate cancer co-authored by US Oncology Research affiliated physician, Nicholas Vogelzang, MD.

"The plenary session will focus on results from an exciting international Phase III clinical trial," said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2012 ASCO Annual Meeting. "This study looked at how androgen deprivation, intermittent versus continuous, affected hormone sensitive metastatic prostate cancer patients."

"Practices and investigators affiliated with US Oncology Research continue to lead the war on cancer through development, collaboration and participation in clinical trials evaluating the latest cutting edge therapies," said Thomas Hutson, DO, PharmD, FACP, oncologist with Texas Oncology and co-chair of the Genitourinary Committee for US Oncology Research. "With more than 60 US Oncology Research affiliated studies being featured at ASCO, this marks one of the most successful years in clinical research for us. In fact, since the mid 1990s, US Oncology Research has enrolled more than 52,000 patients into clinical trials making huge strides in the treatment of cancer across several indications."

A part of McKesson Specialty Health, US Oncology Research enables community-based oncologists, many of whom are affiliated with The US Oncology Network, to participate in clinical research studies. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

Studies that affiliated investigators are part of include:

Oral Presentations:
1. Sunday, June 3, 3:15-3:30pm, N Hall B1 (Plenary Session)
   Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

2. Monday, June 4, 8:00-11:00am, S100bc

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).


3. Saturday, June 2, 1:30-1:45pm, N Hall B1
A phase II/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.
Ian E. Krop, Cristina Saura, Jordi Rodon Ahnert, Carlos Becerra, Carolyn D. Britten, Steven J. Isakoff, David Demanse, Wolfgang Hackl, Cornelia Quadt, Antonio P. Silva, Howard A. Burris, Maysa M. Abu-Khalaf, José Baselga

4. Saturday, June 2, 3:15-3:30pm, E Arie Crown Theater
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

5. Saturday, June 2, 5:15-5:30pm, E Hall D1
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).
Chris Verslype, Allen Lee Cohn, Robin Katie Kelley, Tsai-Shen Yang, Wu-Chou Su, David A. Ramies, Yihua Lee, Xiaodong Shen, Eric Van Cutsem

6. Monday, June 4, 8:45-9:00am, E Arie Crown Theater
Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF V600E melanoma.
Jeffrey Alan Sosman, Anna C. Pavlick, Lynn Mara Schuchter, Karl D Lewis, Grant A. McArthur, Charles Lance Cowey, Stergos J Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Mark Kockx, Olivia Spleiss, Astrid Koehler, Gideon Bollag, Andrew K. Joe, Kerstin Trunzer, Antoni Ribas

7. Tuesday, June 5, 11:00-11:15am, E Arie Crown Theater
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II non-randomized expansion cohort (NRE).
Matthew Raymond Smith, Christopher Sweeney, Dana E. Rathkopf, Howard I. Scher, Christopher Logothetic, Daniel J. George, Celestia S. Higano, Evan Y. Yu, Andrea Lynne Harzstark, Eric Jay Small, A. Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Johann Sebastian De Bono, Naomi B. Haas, Christian Scheffold, Yihua Lee, Paul G. Corn

8. Sunday, June 3, 10:00-10:15am, E Hall D1
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
9. Monday, June 4, 10:15-10:30am, E354a
The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.
John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan Andreas Burger, Kristie A. Blum, Jeff Porter Sharman, Ian W. Flinn, Barbara W. Grant, Nyla A. Heerema, Amy J Johnson, Tasheda Navarro, Danelle Frances James, Eric Hedrick, Susan Mary O'Brien

10. Monday, June 4, 3:30-3:45pm, E Hall D2
SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.

11. Tuesday, June 5, 9:45am-12:45pm, E Arie Crown Theater
Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
Chris Parker, Sten Nilsson, Daniel Heinrich, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiecho, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannisenn, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, A. Oliver Sartor

12. Tuesday, June 5, 9:45am-12:45pm, E Arie Crown Theater
SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).

Posters:
1. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #5B
Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors.

2. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board #9G
Lapatinib in HER2+ early breast cancer: Quality of life analysis.

3. Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #37G
Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer.
Thomas H. Cartwright, Calvin Chao, Margarita Lopatin, Tanya G. Bentley, Michael S. Broder, Eunice Chang

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
4. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #14E
Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).


5. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board #2E
Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.

Joyce O'Shaughnessy, John E. Pippen, Devchand Paul, Christopher T. Stokoe, Joanne Lorraine Blum, Lea Krekow, Frankie Ann Holmes, Christine Lopez-Diaz, Svetsislava J. Vukelja, Deborah Lindquist, Scot M. Sedlacek, Ragene Ruth Rivera, Robert J. Brooks, Kristi McIntyre, Yunfei Wang

6. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #27C
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x10^9/L.


7. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #25C
Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.


8. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #10B
Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community.

Debra A. Patt, Janet L. Espirito, Brian Turnwald, J. Russell Hoverman, Marcus A. Neubauer, Thomas H. Cartwright, Leslie T. Busby, Barry Don Brooks, Mark A. Sitarik, Michael A. Kolodziej, Roy A. Beveridge

9. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #35A
A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.


10. Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #16C
CD30 expression in nonlymphomatous malignancies.

Jeff Porter Sharman, Jerome H. Goldschmidt, John M. Burke, Beth A. Hellerstedt, Kristi McIntyre, Christopher A. Yasenchak, Thomas E. Boyd, Robert L. Ruxer, Dipti Patel-Donnelly, Fadi S. Braiteh, Andres Forero-Torres, Michael A. Savin, Tina Marie Albertson

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
11. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #11G
Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).
Christopher Flowers, Chris L Pashos, Mark Adam Weiss, Nicole Lamanna, Charles Michael Farber, Thomas J. Kipps, Susan Lerner, Neil E Kay, Jeff Porter Sharan, David L. Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S Swern, Zeba M. Khan, Thomas Street, Kristen Sullivan, Michael J. Keating, Ren Yu

12. Monday, June 4, 8:00am-12:00pm, S Hall A2, Poster Board #10C
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.
Guru Sonpavde, Gregory Russell Pond, Stephen John Clarke, Janette L. Vardy, S. L. Wang, Jolanda Paolini, Mariajose Lechuga, M. Dror Michaelson, Matthew Raymond Smith, Isan Chen, Edna Chow Maneval

13. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #10B
Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC).
Teresa Gray Hayes, Guru Sonpavde, Mingjun Wang, Yicheng Wang, Teresa Joe, Martha P. Mims, Michael M. Ittmann, Thomas M. Wheeler, Adrian P. Gee, Rongfu F Wang

14. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #3A
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial.

15. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12E
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Anthony E. Mega, Daniel Peter Petrylak, Philip Kantoff, Joe Stephenson, Nicholas J. Vogelzang, Robert Dreicer, Neal D. Shore, Nancy Stambler, Jennifer Carpenito, Paul D’Ambrosio, Robert Joseph Israel

16. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #34E
MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
Peter Martin, Julie E. Chang, Robert M. Rifkin, Ai-Min Hui, Deborah Berg, Neeraj Gupta, Guohui Liu, Alessandra Di Bacco, Sarit E. Assouline

17. Monday, June 4, 1:15-5:15pm, S Hall A2, Poster Board #51G
Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique.
John R. McGregor, Wolfram E. Samlowski, Shweta Tharkar, Sreekantha Donepudi, Soldano Ferrone

18. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12H
Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
Robert B. Montgomery, Mario A. Eisenberger, Matthew Rettig, Franklin Chu, Roberto Pili, Joe Stephenson, Nicholas J. Vogelzang, Jodie Morrison, Mary-Ellen Taplin

19. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #12F
Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421).

20. Sunday, June 3, 8:00am-12:00pm, S Hall A2, Poster Board #46F
Analysis of a neoadjvant regimen with a fixed dose of doxorubicin followed by a 10-day course of 27 Gy radiation in the treatment of soft tissue sarcoma (STS) of the extremity/trunk.
John Mathews, Gerhard Maale, Donald E. Schwarz, James Fredric Strauss, Mark Feldman, Juan G. Posada, Ashwini Bhat

21. Saturday, June 2, 8:00am-12:00pm, S Hall A2, Poster Board: #47G
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
Eric S. Winer, Howard Safran, Boguslawa Karaszeswska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramla, Kirushna Kumar, Bhabita Mayer, Brendan Mark Johnson, Conrad A. Messam, Yasser Mostafa Mostafa Kamel

Poster Discussions:
1. Monday, June 4, 1:15-5:15pm, E450a, Poster Board #2E
Discussion: 4:45-5:45pm, E Hall D1
Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis.
Daniel D. Von Hoff, Ramesh K. Ramanathan, Douglas B. Evans, Michael J. Demeure, Todd Maney, Brian Wright, Zoran Gatalica, Matthew Jerome McGinniss

2. Saturday, June 2, 8:00am-12:00pm, S405, Poster Board #4
Discussion: 12:00-1:00pm, S406
Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer.
Gayle S. Jameson, Daniel D. Von Hoff, Glen J. Weiss, Donald A. Richards, David A. Smith, Carlos Becerra, Mitchell C. Benson, Zheng Yuan, Deborah A Robins, Michael Turk, Margaret Wagner, Leijun Hu, Boris K. Lin

3. Saturday, June 2, 1:15-5:15pm, S405, Poster Board #15
Discussion: 4:45-5:45pm, S406
A five-arm, open-label, phase I/b study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.

4. Friday, June 1, 1:00-5:00pm, E450b, Poster Board #14
Discussion: 4:30-5:30pm, E Arie Crown Theater

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

5. Sunday, June 3, 1:00-5:00pm, S450b, Poster Board #15
Discussion: 4:00-5:00pm, E Arie Crown Theater
Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials.

6. Sunday, June 3, 1:00-5:00pm, S450b, Poster Board #17
Discussion: 4:00-5:00pm, E Arie Crown Theater
Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

7. Monday, June 4, 1:15-5:15pm, E450b, Poster Board #9
Discussion: 4:45-5:45pm, N Hall B1
Final analysis of phase II study of EZN 2208 (PEG-SN38) in metastatic breast cancer (MBC).
Cynthia R. C. Osborne, Joyce O'Shaughnessy, Frankie Ann Holmes, Hyun Sue Kim, Darren M. Kocs, Michael S. Steinberg, Paul D. Richards, Svetislava J. Vukelja, Noah C. Berkowitz, Aby Buchbinder

8. Monday, June 4, 1:15-5:15pm, E450b, Poster Board #8
Discussion: 4:45-5:45pm, N Hall B1
Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.
Andrew David Seidman, Lee Steven Schwartzberg, Joyce O'Shaughnessy, Gabriella D'Andrea, Peter Rubin, Seth Katz, Hassan Danesi, Loretta Itri, Clifford Hudis

9. Saturday, June 2, 1:15-5:15pm, E450b, Poster Board #16
Discussion: 4:45-5:45pm, E353
CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.
Wolfram E. Samlowski, James Moon, Merle Witter, Michael B. Atkins, John M. Kirkwood, Megan Othus, Antoni Ribas, Vernon K. Sondak, Lawrence E. Flaherty

10. Saturday, June 2, 8:00am-12:00pm, E450a, Poster Board #1
Discussion: 12:00-1:00pm, E Arie Crown Theater
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
11. Saturday, June 2, 8:00am -12:00pm, E450a, Poster Board #5
Discussion: 12:00-1:00pm, E Arie Crown Theater
Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Matt D. Galsky, Susanne Krege, Chia-Chi Lin, Noah M. Hahn, Thorsten Ecke, Erin L. Moshier, Guru Sonpavde, James H. Godbold, William K. Oh, Aristotelis Bamiadis

12. Saturday, June 2, 8:00am-12:00pm, E450a, Poster Board #4
Discussion: 12:00-1:00pm, E Arie Crown Theater
Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).

13. Saturday, June 2, 8:00am-12:00pm, E450b, Poster Board #17
Discussion: 12:00-1:00pm, E354a
Connect MM: The multiple myeloma (MM) disease registry – Incidence of second primary malignancies (SPM).

14. Saturday, June 2, 8:00am-12:00pm, E450b, Poster Board #12
Discussion: 12:00-1:00pm, E354a
Phase Ib trial of AVL-292, a covalent inhibitor of Bruton’s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

15. Friday, June 1, 1:00-5:00pm, E450b, Poster Board #10
Discussion: 4:30-5:30pm, S406
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).

16. Tuesday, June 5, 8:00am-12:00pm, E450a, Poster Board #4
Discussion: 11:30am-12:30pm, E354a
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt, Gerald Edelman, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Xiaodong Shen, David A. Ramies, Michael S. Gordon, Primo Lara

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
17. Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #12
Discussion: 11:30am-12:30pm, E Arie Crown Theater
Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
Oscar B. Goodman, Kim N. Chi, Arturo Molina, Christopher Logothetis, Robert J. Jones, John Staffurth, Scott A. North, Nicholas J. Vogelzang, Fred Saad, Paul N. Mainwaring, Stephen John Harland, Jinhui Li, Thian San Kheoh, Christopher M. Haqq, Howard I. Scher, Karim Fizazi

18. Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #5
Discussion: 11:30am-12:30pm, E Arie Crown Theater
Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).
A. Oliver Sartor, Daniel Heinrich, Joe M. O’Sullivan, Sophie D. Fossa, Ales Chodacki, Pawel J. Wiechno, John P. Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Sten Nilsson, Peter Hoskin, David Bottomley, Robert Edward Coleman, Nicholas J. Vogelzang, C. Gillies O’Bryan-Tear, Jose E. Garcia-Vargas, Minghua Shan, Chris Parker

19. Monday, June 4, 8:00am-12:00pm, E450a, Poster Board #1
Discussion: 11:30am-12:30pm, E Arie Crown Theater
SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR).
Primo Lara, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Erik Gertz, Philip C. Mack, Przemyslaw Twardowski, Nicholas J. Vogelzang, Maha Hussain, Ian Murchie Thompson, Marta Van Loan

20. Monday, June 4, 1:15-5:15pm, E450b, Poster Board: #10
Discussion: 4:45-5:45pm, N Hall B1
Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
Denise Aysel Yardley, Linda D. Bosserman, Nancy Walker Peacock, Anne Favret, Susan Kay Morgan, Victor M. Priego, J. David Bass, Paula L. Griner, Howard A. Burris, John D. Hainsworth, Joyce O'Shaughnessy

Publish Only:
Yen Phung, Zhaohui Wang, Inga Aksamit, Sarah G. Green, Karen Todoroff, Kimberly A. Bergstrom

2. Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy.
Seth P. Lerner, Cora N. Sternberg, Mamoun Younes, Fabio Calabro, Linda Cerbone, A Chandrashekar, Carmen Mitchell, Steven S. Shen, Guru Sonpavde

3. Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors.
Menaka Bhor, Thomas E. Hutson, Rahul Dhanda, Zhimei Liu, Nicholas J. Vogelzang
4. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States.  
Clara Chen, Rohit Borker, Rahul Dhanda, Eric Nadler

Ian D. Schnadig, Thomas E. Hutson, Hsingwen Chung, Rahul Dhanda, Melissa Halm, Michael T. Forsyth, Nicholas J. Vogelzang

6. Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.  

7. Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy.  
David A. Smith, Paul Conkling, Donald A. Richards, Maria Regina C. Flores, John J. Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice Susannah Bexon

8. Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.  
Chris L Pashos, Brian G. Durie, Robert M. Rifkin, Rafat Abounour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Jatin J. Shah, Howard R. Terebelo, Sachdev P. Thomas, Kathleen Tooney, Arlene S Swern, Gale Harding, Kristen Sullivan, Thomas Street, Zeba M. Khan

9. External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC).  
Changhong Yu, Michael W. Kattan, Thomas E. Hutson, Gary R. Hudes, Jinyu Yuan, Olga Valota, Robert John Motzer

10. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem vs. gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.  

11. Pharmacokinetics (PK) of bendamustine when administered in combination with rituximab in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).  
Mary Bond, John M. Burke, Edward Hellriegel, Philmore Robertson, Luann Phillips, Elizabeth Ludwig, Mona Darwish

12. A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).  

13. Oral low-dose cyclophosphamide, as a second-line agent, in patients with primary docetaxel refractory metastatic castration-resistant prostate cancer (mCRPC).
Daniela Shapiro, James Thomas Symanowski, Nicholas J. Vogelzang, Oscar B. Goodman

About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 85 practices in more than 245 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 52,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

About The US Oncology Network
The US Oncology Network is one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. Like-minded physicians are united through The Network around a common vision of expanding patient access to high-quality, integrated cancer care in communities throughout the nation. Leveraging healthcare information technology, shared best practices, refined evidence-based medicine guidelines, and quality measurements, physicians affiliated with The US Oncology Network are committed to advancing the quality, safety, and science of cancer care to improve patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system to advance the science, technology and quality of care. For more information, visit www.usoncology.com.

About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.

About McKesson
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.

Media Contact:
Claire Crye
(281) 863-6783 / (281) 825-9927
Claire.Crye@mckesson.com

###